<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glycopyrrolate (glycopyrronium) (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glycopyrrolate (glycopyrronium) (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Glycopyrrolate (glycopyrronium) (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="107362" href="/d/html/107362.html" rel="external">see "Glycopyrrolate (glycopyrronium) (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="107360" href="/d/html/107360.html" rel="external">see "Glycopyrrolate (glycopyrronium) (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45524990"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cuvposa;</li>
<li>Dartisla ODT [DSC];</li>
<li>Glycate;</li>
<li>Glyrx-PF;</li>
<li>Robinul;</li>
<li>Robinul-Forte</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872063"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cuvposa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F45524995"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F45525041"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Orally disintegrating tablet 1.7 mg = Regular tablet 2 mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e52912dd-2983-4445-8d7d-632db996bfec">Primary focal hyperhidrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary focal hyperhidrosis (off-label use): Limited data available: Oral:</b> 1 to 2 mg once or twice daily may be a typical effective dosage range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21820204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21820204'])">Ref</a></span>); titrate per response and tolerability; doses up to 6 to 8 mg per day in 2 or 3 divided doses have been used in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17459043','lexi-content-ref-17661933','lexi-content-ref-21820204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17459043','lexi-content-ref-17661933','lexi-content-ref-21820204'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="787b60a8-37d5-49b7-b4c9-e27a3d347ac2">Reduction of secretions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of secretions (preoperative): IM:</b> 4 mcg/kg 30 to 60 minutes before anesthesia or when the preanesthetic opioid and/or sedative are administered</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85dc72d2-6d4b-47cc-b71f-2ecb4e78d19f">Reduction of secretions at end of life</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of secretions at end of life (death rattle) (off-label use): IV, SUBQ:</b> 0.2 mg every 4 to 8 hours as needed; do not exceed 4 doses/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26699170','lexi-content-ref-19233993']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26699170','lexi-content-ref-19233993'])">Ref</a></span>) <b>or</b> 0.4 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19116709','lexi-content-ref-22964342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19116709','lexi-content-ref-22964342'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f307b7b5-d7c3-47a1-a551-33e76a93e77c">Reversal of bradycardia, vagal reflexes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of bradycardia, vagal reflexes (intraoperative): IV:</b> 0.1 mg as a single dose; repeat as needed at 2- to 3-minute intervals</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd2fac6f-ed36-438f-9f2c-b07eaa73bb2f">Reversal of muscarinic effects of cholinergic agents</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of muscarinic effects of cholinergic agents: IV:</b> 0.2 mg for each 1 mg of neostigmine or 5 mg of pyridostigmine administered</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991599"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; elimination is severely impaired in renal failure; use with caution; dosage adjustment may be necessary.</p></div>
<div class="block doha drugH1Div" id="F50988807"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; use with caution; consider dose reduction.</p></div>
<div class="block doe drugH1Div" id="F45525042"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use with caution; consider dose reduction.</p></div>
<div class="block dop drugH1Div" id="F45525040"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="107360" href="/d/html/107360.html" rel="external">see "Glycopyrrolate (glycopyrronium) (systemic): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Dosing may be presented as mcg/kg or <b>mg</b>/dose; use extra caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d66ab3f-5bae-4acc-9e7b-434c45ace118">Chronic drooling</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic drooling:</b> Children ≥3 years and Adolescents ≤16 years: Oral solution (Cuvposa): 20 mcg/kg/dose 3 times daily; titrate in increments of 20 mcg/kg/dose every 5 to 7 days as tolerated to response up to a maximum dose of 100 mcg/kg/dose 3 times daily, not to exceed 1,500 to 3,000 mcg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e52912dd-2983-4445-8d7d-632db996bfec">Primary focal hyperhidrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary focal hyperhidrosis: </b>Limited data available; optimal dose not established:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years and Adolescents: Oral: Usual dose: 1 to 2 <b>mg</b> once or twice daily; titrate per response and tolerability; reported range: 0.5 to 6 <b>mg</b> per <b>day</b> in divided doses one to three times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25152346','lexi-content-ref-24266878','lexi-content-ref-22405644','lexi-content-ref-34409395','lexi-content-ref-33660889','lexi-content-ref-21820204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25152346','lexi-content-ref-24266878','lexi-content-ref-22405644','lexi-content-ref-34409395','lexi-content-ref-33660889','lexi-content-ref-21820204'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4680a7d7-7f92-49ac-8908-3a20cc956e65">Reduction of respiratory secretions, palliative care</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of respiratory secretions, palliative care:</b> Limited data available: Children: Oral: 40 to 100 mcg/kg/dose every 4 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ullrich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ullrich.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2b3a477-72f8-459b-b3a9-489de3019e5b">Reduction of secretions, preoperative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of secretions, preoperative:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤2 years: IM: 4 to 9 mcg/kg as a single dose 30 to 60 minutes before procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;2 years and Adolescents: IM: 4 mcg/kg as a single dose 30 to 60 minutes before procedure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f307b7b5-d7c3-47a1-a551-33e76a93e77c">Reversal of bradycardia, vagal reflexes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of bradycardia, vagal reflexes (intraoperative):</b> Infants, Children, and Adolescents: IV: 4 mcg/kg/dose (maximum dose: 100 mcg/dose) at 2- to 3-minute intervals.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd2fac6f-ed36-438f-9f2c-b07eaa73bb2f">Reversal of muscarinic effects of cholinergic agents</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of muscarinic effects of cholinergic agents:</b> Infants, Children, and Adolescents: IV: 0.2 <b>mg</b> for each 1 mg of neostigmine or 5 mg of pyridostigmine administered.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112337"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; elimination is severely impaired in renal failure; use with caution; dosage adjustment may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51112338"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block arsc drugH1Div" id="F58625973"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic agents, including systemic glycopyrrolate, may cause reversible, dose-dependent anticholinergic effects, including, but not limited to, CNS effects (eg, <b>behavioral changes</b> [eg, <b>irritability</b>, <b>agitation</b>,<b> dizziness, headache</b>]); genitourinary effects (eg, <b>urinary retention</b>); GI effects (eg, <b>xerostomia,</b>
<b>constipation, gastrointestinal pseudo-obstruction</b>); ophthalmic effects (eg, <b>blurred vision, mydriasis</b>); cardiovascular effects (eg, <b>palpitations</b>); and dermatologic effects (eg, hypohidrosis) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9729704','lexi-content-ref-30905688','lexi-content-ref-18217788','lexi-content-ref-27976476','lexi-content-ref-22445330','lexi-content-ref-11115305','lexi-content-ref-32890297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9729704','lexi-content-ref-30905688','lexi-content-ref-18217788','lexi-content-ref-27976476','lexi-content-ref-22445330','lexi-content-ref-11115305','lexi-content-ref-32890297'])">Ref</a></span>). <b>Xerostomia</b> is the most frequent adverse reaction resulting in discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17459043','lexi-content-ref-21820204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17459043','lexi-content-ref-21820204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; an extension of antimuscarinic pharmacological properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9729704','lexi-content-ref-30905688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9729704','lexi-content-ref-30905688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22405644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22405644'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other anticholinergic medications</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various GI effects may occur with systemic glycopyrrolate, including<b> xerostomia, constipation, </b>and <b>gastrointestinal</b>
<b>pseudo-obstruction</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22445330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22445330'])">Ref</a></span>). <b>Diarrhea</b> may be an early sign of incomplete intestinal obstruction, especially in patients with an ileostomy or colostomy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; an extension of antimuscarinic pharmacological properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9729704','lexi-content-ref-30905688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9729704','lexi-content-ref-30905688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Mechanical GI obstructive diseases (contraindicated)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI motility disorders (contraindicated)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications that affect GI peristalsis</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Heat prostration</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic agents, including systemic glycopyrrolate, may cause hypohidrosis, which may result in life-threatening hyperthermia or heatstroke (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18217788','lexi-content-ref-23261898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18217788','lexi-content-ref-23261898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Antagonism of central and peripheral muscarinic receptors results in increased heat production due to increased muscle activity and impaired sweat gland function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23261898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23261898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Physical exertion in high ambient temperature and humidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6831343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6831343'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33758045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33758045'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and older adults</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F45525008"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences reported with oral use of glycopyrrolate in children and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (35%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 1</a>)</span><span class="table-link" style="display:none;">Constipation</span>, vomiting (40%), xerostomia (40%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia')">table 2</a>)</span><span class="table-link" style="display:none;">Xerostomia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Glycopyrrolate (Systemic): Adverse Reaction: Constipation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pediatric patients 3 to 16 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mcg/kg/dose 3 times daily, titrate in increments of 20 mcg/kg/dose every 5 to 7 days up to a maximum dose of 100 mcg/kg/dose 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral solution</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic drooling</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia" frame="border" id="lexi-content-xerostomia" rules="all">
<caption style="text-align:center;">
<b>Glycopyrrolate (Systemic): Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pediatric patients 3 to 16 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mcg/kg/dose 3 times daily, titrate in increments of 20 mcg/kg/dose every 5 to 7 days up to a maximum dose of 100 mcg/kg/dose 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral solution</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic drooling</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (15%)<span class="lexi-table-link-container"> (<a aria-label="Urinary Retention table link" class="lexi-table-link" data-table-id="lexi-content-urinary-retention" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-urinary-retention')">table 3</a>)</span><span class="table-link" style="display:none;">Urinary Retention</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Urinary Retention" frame="border" id="lexi-content-urinary-retention" rules="all">
<caption style="text-align:center;">
<b>Glycopyrrolate (Systemic): Adverse Reaction: Urinary Retention</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pediatric patients 3 to 16 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mcg/kg/dose 3 times daily, titrate in increments of 20 mcg/kg/dose every 5 to 7 days up to a maximum dose of 100 mcg/kg/dose 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral solution</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic drooling</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (15%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 4</a>)</span><span class="table-link" style="display:none;">Headache</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Glycopyrrolate (Systemic): Adverse Reaction: Headache</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Glycopyrrolate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pediatric patients 3 to 16 years</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mcg/kg/dose 3 times daily, titrate in increments of 20 mcg/kg/dose every 5 to 7 days up to a maximum dose of 100 mcg/kg/dose 3 times daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral solution</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic drooling</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (30%), sinusitis (15%), upper respiratory tract infection (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all routes of administration and ages):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (including bradycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, palpitations (Cruddas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cheilosis (Eiland 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, diarrhea (Eiland 2012), gastrointestinal pseudo-obstruction (Eiland 2012), halitosis (Eiland 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Lactation insufficiency (suppression)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial swelling (Cruddas 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including erythema at injection site, injection-site pruritus, localized edema, pain at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (Eiland 2012), behavioral changes (Eiland 2012), dizziness (Cruddas 2017), irritability (Eiland 2012), personality changes (Eiland 2012), seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (Cruddas 2017), mydriasis (Eiland 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (Eiland 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Chabicovsky 2019), malignant hyperthermia</p></div>
<div class="block coi drugH1Div" id="F45525005"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to glycopyrrolate or any component of the formulation; medical conditions that preclude use of anticholinergic medication (eg, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, paralytic ileus, obstructive disease of GI tract [eg, achalasia, pyloroduodenal stenosis, strictures], bleeding GI ulcer, intestinal atony in older adult or debilitated patients, unstable cardiovascular status in acute hemorrhage, glaucoma, obstructive uropathy [eg, bladder neck obstruction due to prostatic hypertrophy], myasthenia gravis)</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Additional contraindication: Concomitant use of potassium chloride in a solid oral dosage form.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Injection: Use in newborns; chronic lung disease in older adult or debilitated patients.</p></div>
<div class="block war drugH1Div" id="F45525006"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI transit: Slowing of GI muscular action can occur resulting in constipation or intestinal pseudo-obstruction. Constipation is a common dose-limiting adverse event. Intestinal pseudo-obstruction can result in abdominal distention, pain, nausea, or vomiting; discontinue if these symptoms develop or worsen during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heat prostration: May occur in the presence of fever, increased environmental temperature, and/or during physical exercise, particularly in children and the elderly; use caution in hot weather and/or exercise. Avoid exertion and high environmental temperature after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mechanical obstruction (incomplete): Diarrhea may be an early sign of incomplete intestinal obstruction, especially in patients with an ileostomy or colostomy; avoid use in these patients. Discontinue treatment if incomplete mechanical intestinal obstruction is suspected or if diarrhea occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with coronary artery disease, arrhythmias, heart failure, hypertension, or tachycardia; evaluate tachycardia prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; consider dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hiatal hernia: Use with caution in patients with hiatal hernia with reflux esophagitis; consider dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropathy: Use with caution in patients with autonomic neuropathy; consider dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/bladder neck obstruction: May worsen the symptoms (eg, urinary retention) of prostatic hyperplasia and/or bladder neck obstruction; use with caution; consider dosage reduction in patients with prostatic hypertrophy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; elimination is severely impaired in renal failure; dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ulcerative colitis: Use with caution in patients with ulcerative colitis; large doses may suppress intestinal motility; consider dosage reduction; may precipitate/exacerbate an ileus or toxic megacolon. Use is contraindicated in patients with severe ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; increased risk for anticholinergic effects, confusion, and hallucinations; consider dosage reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Infants, patients with Down syndrome, and pediatric patients with spastic paralysis or brain damage may experience an increased response to anticholinergics, increasing the potential for adverse events. A paradoxical reaction characterized by hyperexcitability may occur in pediatric patients taking large doses. Infants and young children are especially susceptible to the toxic effects of anticholinergics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Sensitivity of the eyes to light may occur. Protect eyes from light after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878809"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F45525060"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glyrx-PF: 0.2 mg/mL (1 mL); 0.4 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL, 2 mL); 0.4 mg/2 mL (2 mL); 1 mg/5 mL (5 mL); 4 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL); 0.4 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cuvposa: 1 mg/5 mL (473 mL) [contains methylparaben, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/5 mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glyrx-PF: 0.6 mg/3 mL (3 mL); 1 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL); 0.4 mg/2 mL (2 mL); 0.6 mg/3 mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glycate: 1.5 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glycate: 1.5 mg [dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Robinul: 1 mg [scored; dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Robinul-Forte: 2 mg [scored; dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 1.5 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dartisla ODT: 1.7 mg [DSC] [contains gelatin (fish)]</p></div>
<div class="block geq drugH1Div" id="F45524993"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F45525064"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cuvposa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/5 mL (per mL): $1.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Glycopyrrolate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/mL (per mL): $0.84 - $16.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/2 mL (per mL): $2.40 - $14.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/5 mL (per mL): $0.66 - $11.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/20 mL (per mL): $1.44 - $8.93</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Glycopyrrolate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/5 mL (per mL): $0.96 - $1.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Glyrx-PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/mL (per mL): $4.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/2 mL (per mL): $3.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Glycopyrrolate PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/mL (per mL): $8.38 - $8.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/2 mL (per mL): $8.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/3 mL (per mL): $6.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Glyrx-PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/3 mL (per mL): $4.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/5 mL (per mL): $3.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Glycate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $19.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Glycopyrrolate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $1.06 - $1.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $39.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.76 - $2.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Robinul Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $11.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Robinul-Forte Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $18.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872064"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2 mg/mL (1 mL, 2 mL, 20 mL); 0.4 mg/2 mL (2 mL); 4 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cuvposa: 1 mg/5 mL (473 mL) [contains methylparaben, propylene glycol, propylparaben, saccharin sodium, sorbitol]</p></div>
<div class="block adm drugH1Div" id="F45525045"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> May administer undiluted.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> May be administered IV without dilution or may dilute in a compatible solution. In perioperative setting, usually administered over 1 to 2 minutes (eg, in adults: 0.2 mg over 1 to 2 minutes). May also be administered via the tubing of a running IV infusion of a NS. May be administered IV in the same syringe with neostigmine or pyridostigmine for reversal of neuromuscular blockade.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Administer at least 1 hour before or 2 hours after food. Remove tablet from blister packaging immediately prior to administration; do not push tablet through foil. Place tablet on tongue and allow to disintegrate then swallow without water. <b>Tablets should not be broken or cut.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Administer 1 hour before or 2 hours after meals. Measure oral solution with an accurate measuring device (eg, dosing cup, oral syringe).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ (off-label route):</b> May administer SUBQ (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26699170','lexi-content-ref-19233993','lexi-content-ref-22964342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26699170','lexi-content-ref-19233993','lexi-content-ref-22964342'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614630"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Administer on an empty stomach, 1 hour before or 2 hours after meals; measure with an accurate measuring device (eg, dosing cup, oral syringe).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May be administered IM (undiluted) or by slow IV injection (with or without dilution in a compatible fluid); in perioperative setting, usually administered over 1 to 2 minutes (eg, in adults: 0.2 mg over 1 to 2 minutes). May also be administered via the tubing of a running IV infusion of NS. May be administered IV in the same syringe with neostigmine or pyridostigmine for reversal of neuromuscular blockade.</p></div>
<div class="block use drugH1Div" id="F45524999"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic drooling (Cuvposa only):</b> To reduce chronic, severe drooling in pediatric patients 3 to 16 years with neurologic conditions (eg, cerebral palsy) associated with problem drooling</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of secretions (injection only):</b> To reduce salivary, tracheobronchial, and pharyngeal secretions and to reduce the volume and acidity of gastric secretions during induction of anesthesia and intubation</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of bradycardia, vagal reflexes (injection only):</b> To block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation; intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of muscarinic effects of cholinergic agents (injection only):</b> Protects against the peripheral muscarinic effects (eg, bradycardia, excessive secretions) of cholinergic agents (eg, neostigmine, pyridostigmine) given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants</p></div>
<div class="block off-label drugH1Div" id="F45525000"><span class="drugH1">Use: Off-Label: Adult</span><p>Reduction of secretions at end of life (death rattle); Primary focal hyperhidrosis</p></div>
<div class="block mst drugH1Div" id="F45524987"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Robinul [US and multiple international markets] may be confused with Reminyl brand name for galantamine [Canada and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45525015"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45525012"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Glycopyrrolate (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atenolol: Glycopyrrolate (Systemic) may increase the serum concentration of Atenolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Glycopyrrolate (Systemic) may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Glycopyrrolate (Systemic) may decrease the serum concentration of Haloperidol.  Management: Consider avoiding concurrent use of glycopyrrolate and haloperidol.Monitor patients closely for signs/symptoms of reduced clinical response to haloperidol if concurrent use with glycopyrrolate is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Glycopyrrolate (Systemic) may decrease the serum concentration of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Glycopyrrolate (Systemic) may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F45525020"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration with a high-fat meal significantly reduced absorption. Management: Administer at least 1 hour before or 2 hours after meals.</p></div>
<div class="block pri drugH1Div" id="F45525002"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">When given as a single maternal injection prior to delivery, glycopyrrolate was not found to cross the placenta in significant amounts. In addition, fetal heart rate, fetal heart rate variability, and Apgar scores were not significantly affected (Abboud 1981; Abboud 1983; Ali-Melkkilä 1990; Ure 1999).</p>
<p style="text-indent:0em;margin-top:2em;">Use of topical glycopyrrolate for the treatment of hyperhidrosis in a pregnant patient diagnosed with herpetic neuralgia has been described in a case report (Ladjevic 2009).</p></div>
<div class="block brc drugH1Div" id="F45525003"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if glycopyrrolate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Glycopyrrolate is an anticholinergic and may suppress lactation.</p></div>
<div class="block mop drugH1Div" id="F45525051"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate; anticholinergic effects; bowel sounds; bowel movements; effects on drooling</p></div>
<div class="block pha drugH1Div" id="F45525024"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; indirectly reduces the rate of salivation by preventing the stimulation of acetylcholine receptors</p></div>
<div class="block phk drugH1Div" id="F45525026"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IM: 15 to 30 minutes; IV: Within 1 minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: IM: Within ~30 to 45 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Vagal effect: 2 to 3 hours; Inhibition of salivation: Up to 7 hours; Parenteral: 7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral tablet: Poor (~3%); variable and erratic; Oral solution: 23% lower compared to tablet; high-fat meal markedly reduces the oral bioavailability.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: Children and Adolescents ≤14 years: 1.3 to 1.8 L/kg (range: 0.7 to 3.9 L/kg); Adults: 0.42 ± 0.22 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: 3%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: Infants: 21.6 to 130 minutes; Children: 19.2 to 99.2 minutes; IM: Adults: 0.55 to 1.25 hours; IV: 0.83 ± 0.27 hour; Oral solution: Adults: 3 hours; Orally disintegrating tablet: Adults: 2.8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: IM: ~30 minutes; Oral solution: 3.1 hours; Orally disintegrating tablet: Median: 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as unchanged drug, IM: &gt;80%, IV: 85%); bile (as unchanged drug, &lt;5%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Children and Adolescents ≤14 years: Mean range: 1.01 to 1.41 L/kg/hour (range: 0.32 to 2.22 L/kg/hour); Adults: 0.54 ± 0.14 L/kg/hour.</p></div>
<div class="block phksp drugH1Div" id="F51196148"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination is severely impaired in patients with renal failure.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46330001"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Robanul</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gastrodyn | Robinul | Tarodyl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Glycopyrronium | Robinul</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Glycopyrrolate | Robinul</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Gcolate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Contrem | Geschnal | Robinul | Sroton</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Glycopyrrolate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dartisla odt | Glycopyrrolate | Glyrx pf | Robinul</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Gastrodyn | Robin | Robinul</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Robinul</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-6829946">
<a name="6829946"></a>Abboud T, Raya J, Sadri S, Grobler N, Stine L, Miller F. Fetal and maternal cardiovascular effects of atropine and glycopyrrolate. <i>Anesth Analg.</i> 1983;62(4):426-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/6829946/pubmed" id="6829946" target="_blank">6829946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7465128">
<a name="7465128"></a>Abboud TK, Read J, Miller F, Chen T, Valle R, Henriksen EH. Use of glycopyrrolate in the parturient: effect on the maternal and fetal heart and uterine activity. <i>Obstet Gynecol</i>. 1981;57(2):224-227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/7465128/pubmed" id="7465128" target="_blank">7465128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2400072">
<a name="2400072"></a>Ali-Melkkilä T, Kaila T, Kanto J, Iisalo E. Pharmacokinetics of glycopyrronium in parturients. <i>Anaesthesia</i>. 1990;45(8):634-637. doi:10.1111/j.1365-2044.1990.tb14385.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/2400072/pubmed" id="2400072" target="_blank">2400072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9729704">
<a name="9729704"></a>Bachrach SJ, Walter RS, Trzcinski K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. <i>Clin Pediatr (Phila)</i>. 1998;37(8):485-490. doi:10.1177/000992289803700805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/9729704/pubmed" id="9729704" target="_blank">9729704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17459043">
<a name="17459043"></a>Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. <i>Br J Dermatol</i>. 2007;157(1):118-121. doi:10.1111/j.1365-2133.2007.07884.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/17459043/pubmed" id="17459043" target="_blank">17459043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26699170">
<a name="26699170"></a>Blinderman CD, Billings JA. Comfort care for patients dying in the hospital. <i>N Engl J Med</i>. 2015;373(26):2549-2561. doi:10.1056/NEJMra1411746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/26699170/pubmed" id="26699170" target="_blank">26699170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30905688">
<a name="30905688"></a>Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C. Pharmacology, toxicology and clinical safety of glycopyrrolate. <i>Toxicol Appl Pharmacol</i>. 2019;370:154-169. doi:10.1016/j.taap.2019.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/30905688/pubmed" id="30905688" target="_blank">30905688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18217788">
<a name="18217788"></a>Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. <i>Drug Saf</i>. 2008;31(2):109-126. doi:10.2165/00002018-200831020-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/18217788/pubmed" id="18217788" target="_blank">18217788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27976476">
<a name="27976476"></a>Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(6):952-963. doi:10.1111/jdv.14081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/27976476/pubmed" id="27976476" target="_blank">27976476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cuvposa.1">
<a name="Cuvposa.1"></a>Cuvposa (glycopyrrolate) [prescribing information]. Greensboro, NC: Merz Pharmaceuticals LLC; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cuvposa.2">
<a name="Cuvposa.2"></a>Cuvposa (glycopyrrolate) [prescribing information]. Raleigh, NC: Merz North America Inc; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cuvposa.3">
<a name="Cuvposa.3"></a>Cuvposa (glycopyrrolate) [prescribing information]. Raleigh, NC: Merz Pharmaceuticals LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dartisla.1">
<a name="Dartisla.1"></a>Dartisla (glycopyrrolate) [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals LLC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dartisla.2">
<a name="Dartisla.2"></a>Dartisla (glycopyrrolate) [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals LLC; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22445330">
<a name="22445330"></a>Eiland LS. Glycopyrrolate for chronic drooling in children. <i>Clin Ther</i>. 2012;34(4):735-742. doi:10.1016/j.clinthera.2012.02.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/22445330/pubmed" id="22445330" target="_blank">22445330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25152346">
<a name="25152346"></a>Glaser DA. Oral medications. <i>Dermatol Clin</i>. 2014;32(4):527-532. doi:10.1016/j.det.2014.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/25152346/pubmed" id="25152346" target="_blank">25152346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glycate.1">
<a name="Glycate.1"></a>Glycate (glycopyrrolate, USP) [prescribing information]. Las Vegas, NV: Intra-Sana Laboratories LLC; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glycopyrrolate.1">
<a name="Glycopyrrolate.1"></a>Glycopyrrolate injection [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glycopyrrolate.5">
<a name="Glycopyrrolate.5"></a>Glycopyrrolate injection, USP [prescribing information]. Chicago, IL: Meitheal Pharmaceuticals; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glycopyrrolate.2">
<a name="Glycopyrrolate.2"></a>Glycopyrrolate injection, USP [prescribing information]. Chicago, IL: Meitheal Pharmaceuticals; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glycopyrrolate.3">
<a name="Glycopyrrolate.3"></a>Glycopyrrolate injection, prefilled syringe [prescribing information]. Lake Zurich, IL: Fresenius Kabi; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glycopyrrolate.4">
<a name="Glycopyrrolate.4"></a>Glycopyrrolate tablets [prescribing information]. East Brunswick, NJ: Rising Pharma Holdings Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glyrx-PF.1">
<a name="Glyrx-PF.1"></a>Glyrx-PF (glycopyrrolate) [prescribing information]. Lenoir, NC: Exela Pharma Sciences LLC; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19233993">
<a name="19233993"></a>Kintzel PE, Chase SL, Thomas W, Vancamp DM, Clements EA. Anticholinergic medications for managing noisy respirations in adult hospice patients. <i>Am J Health Syst Pharm</i>. 2009;66(5):458-464. doi:10.2146/ajhp080194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/19233993/pubmed" id="19233993" target="_blank">19233993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24266878">
<a name="24266878"></a>Kumar MG, Foreman RS, Berk DR, Bayliss SJ. Oral glycopyrrolate for refractory pediatric and adolescent hyperhidrosis. <i>Pediatr Dermatol</i>. 2014;31(1):e28-e30. doi:10.1111/pde.12236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/24266878/pubmed" id="24266878" target="_blank">24266878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20176672">
<a name="20176672"></a>Kumar P, Denson SE, Mancuso TJ, et al. Premedication for Nonemergency Endotracheal Intubation in the Neonate. <i>Pediatrics</i>. 2010;125(3):608-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/20176672/pubmed" id="20176672" target="_blank">20176672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19430567">
<a name="19430567"></a>Ladjevic NG, Likic-Ladjevic IS. Topical glycopirrolate for the management of hyperhidrosis in herpetic neuralgia. <i>Yonsei Med J.</i> 2009;50(2):293-295. doi:10.3349/ymj.2009.50.2.293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/19430567/pubmed" id="19430567" target="_blank">19430567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22259713">
<a name="22259713"></a>Lee HH, Kim DW, Kim DW, Kim C. Efficacy of glycopyrrolate in primary hyperhidrosis patients. <i>Korean J Pain</i>. 2012;25(1):28-32. doi:10.3344/kjp.2012.25.1.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/22259713/pubmed" id="22259713" target="_blank">22259713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19116709">
<a name="19116709"></a>Likar R, Rupacher E, Kager H, Molnar M, Pipam W, Sittl R. Efficacy of glycopyrronium bromide and scopolamine hydrobromide in patients with death rattle: a randomized controlled study [in German]. <i>Wien Klin Wochenschr</i>. 2008;120(21-22):679-683. doi:10.1007/s00508-008-1094-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/19116709/pubmed" id="19116709" target="_blank">19116709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33758045">
<a name="33758045"></a>Manivannan A, Kabbani D, Levine D. Use of multiple anticholinergic medications can predispose patients to severe non-exertional hyperthermia. <i>BMJ Case Rep</i>. 2021;14(3):e239873. doi:10.1136/bcr-2020-239873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/33758045/pubmed" id="33758045" target="_blank">33758045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11115305">
<a name="11115305"></a>Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. <i>Arch Pediatr Adolesc Med</i>. 2000;154(12):1214-1218. doi:10.1001/archpedi.154.12.1214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/11115305/pubmed" id="11115305" target="_blank">11115305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32890297">
<a name="32890297"></a>Mormol JD, Basques BA, Harada GK, et al. Risk factors associated with development of urinary retention following posterior lumbar spinal fusion: Special attention to the use of glycopyrrolate in anesthesia reversal. <i>Spine (Phila Pa 1976)</i>. 2021;46(2):E133-E138. doi:10.1097/BRS.0000000000003678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/32890297/pubmed" id="32890297" target="_blank">32890297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23261898">
<a name="23261898"></a>Musselman ME, Saely S. Diagnosis and treatment of drug-induced hyperthermia. <i>Am J Health Syst Pharm</i>. 2013;70(1):34-42. doi:10.2146/ajhp110543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/23261898/pubmed" id="23261898" target="_blank">23261898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15283837">
<a name="15283837"></a>Nilsson E, Ingvarsson L, Isern E. Treacher Collins Syndrome With Choanal Atresia: One Way to Handle the Airway. <i>Paediatr Anaesth</i>. 2004;14(8):700-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/15283837/pubmed" id="15283837" target="_blank">15283837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21798556">
<a name="21798556"></a>Norman E, Wikström S, Hellström-Westas L, Turpeinen U, Hämäläinen E, Fellman V. Rapid sequence induction is superior to morphine for intubation of preterm infants: a randomized controlled trial. <i>J Pediatr</i>. 2011;159(6):893-9.e1. doi:10.1016/j.jpeds.2011.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/21798556/pubmed" id="21798556" target="_blank">21798556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22405644">
<a name="22405644"></a>Paller AS, Shah PR, Silverio AM, Wagner A, Chamlin SL, Mancini AJ. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. <i>J Am Acad Dermatol</i>. 2012;67(5):918-923. doi:10.1016/j.jaad.2012.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/22405644/pubmed" id="22405644" target="_blank">22405644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34409395">
<a name="34409395"></a>Park HH, Conic RRZ, Zhang S, Lieu A, Haft M, Hightower GK. Oral glycopyrrolate for primary focal hyperhidrosis in a pediatric population: a cross-sectional study. <i>JAAD Int</i>. 2021;4:65-66. doi:10.1016/j.jdin.2021.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/34409395/pubmed" id="34409395" target="_blank">34409395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22964342">
<a name="22964342"></a>Prommer E. Anticholinergics in palliative medicine: an update. <i>Am J Hosp Palliat Care</i>. 2013;30(5):490-498. doi:10.1177/1049909112459366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/22964342/pubmed" id="22964342" target="_blank">22964342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33660889">
<a name="33660889"></a>Remington C, Ruth J, Hebert AA. Primary hyperhidrosis in children: a review of therapeutics. <i>Pediatr Dermatol</i>. 2021;38(3):561-567. doi:10.1111/pde.14551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/33660889/pubmed" id="33660889" target="_blank">33660889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Robinul.1">
<a name="Robinul.1"></a>Robinul and Robinul Forte (glycopyrrolate) tablets [prescribing information]. East Brunswick, NJ: Casper Pharma LLC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17661933">
<a name="17661933"></a>Solish N, Bertucci V, Dansereau A, et al; Canadian Hyperhidrosis Advisory Committee. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. <i>Dermatol Surg</i>. 2007;33(8):908-923. doi:10.1111/j.1524-4725.2007.33192.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/17661933/pubmed" id="17661933" target="_blank">17661933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6831343">
<a name="6831343"></a>Stadnyk AN, Glezos JD. Drug-induced heat stroke. <i>Can Med Assoc J</i>. 1983;128(8):957-959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/6831343/pubmed" id="6831343" target="_blank">6831343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ullrich.1">
<a name="Ullrich.1"></a>Ullrich C, Duncan J, Joselow M, Wolfe J. Pediatric palliative care. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 7.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10365009">
<a name="10365009"></a>Ure D, James KS, McNeill M, Booth JV. Glycopyrrolate reduces nausea during spinal anaesthesia for caesarean section without affecting neonatal outcome. <i>Br J Anaesth</i>. 1999;82(2):277-279. doi:10.1093/bja/82.2.277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/10365009/pubmed" id="10365009" target="_blank">10365009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21820204">
<a name="21820204"></a>Walling HW. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. <i>J Am Acad Dermatol</i>. 2012;66(3):387-392. doi:10.1016/j.jaad.2011.01.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/21820204/pubmed" id="21820204" target="_blank">21820204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glycopyrrolate-glycopyrronium-systemic-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107359 Version 497.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
